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Mutations in MPZ, the gene encoding myelin protein zero (MPZ), the major protein constituent of peripheral
myelin, can cause the adult-onset, inherited neuropathy Charcot-Marie-Tooth disease, as well as the more severe,
childhood-onset Dejerine-Sottas neuropathy and congenital hypomyelinating neuropathy. Most MPZ-truncating
mutations associated with severe forms of peripheral neuropathy result in premature termination codons within
the terminal or penultimate exons that are not subject to nonsense-mediated decay and are stably translated into
mutant proteins with potential dominant-negative activity. However, some truncating mutations at the 3′ end of
MPZ escape the nonsense-mediated decay pathway and cause a mild peripheral neuropathy phenotype.We examined
the functional properties of MPZ-truncating proteins that escaped nonsense-mediated decay, and we found that
frameshift mutations associated with severe disease cause an intracellular accumulation of mutant proteins, primarily
within the endoplasmic reticulum (ER), which induces apoptosis. Curcumin, a chemical compound derived from
the curry spice tumeric, releases the ER-retained MPZ mutants into the cytoplasm accompanied by a lower number
of apoptotic cells. Our ﬁndings suggest that curcumin treatment is sufﬁcient to relieve the toxic effect of mutant
aggregation-induced apoptosis and may potentially have a therapeutic role in treating selected forms of inherited
peripheral neuropathies.
Introduction
Mutations in the gene encoding myelin protein zero
(MPZ) cause dominantly inherited peripheral neuropa-
thies that range in severity from adult-onset Charcot-
Marie-Tooth disease (CMT) type 1B (CMT1B [MIM
118200]) to childhood-onset Dejerine-Sottas neuropa-
thy (DSN [MIM 145900]) or congenital hypomyelinat-
ing neuropathy (CHN [MIM 605253]) (Lupski and Gar-
cia 2001). CMT1B, a demyelinating neuropathy that
results in progressive distal muscle atrophy, is charac-
terized by a symmetrically slowed motor nerve conduc-
tion velocity (Shy et al. 2005). DSN is a more severe
form of CMT that has an earlier onset of clinical symp-
toms, evidenced by the delayed achievement of motor-
skill milestones. Clinical ﬁndings include hypertrophied
nerves, increased cerebrospinal ﬂuid protein, and, com-
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pared with CMT, more-signiﬁcant slowing of nerve con-
duction velocity, more-pronounced demyelination, and
neuropathology signiﬁcant for more-numerous onion
bulbs (Hayasaka et al. 1993; Rautenstrauss et al. 1994).
The related CHN presents at birth and is distinguished
from DSN by its congenital manifestations and, in some
cases, the absence of myelin (Harati and Butler 1985).
We previously documented that the nonsense-medi-
ated degradation of mRNA carrying premature termi-
nation codons in upstream exons is a mechanism for
MPZ haploinsufﬁciency alleles (Inoue et al. 2004). The
nonsense-mediated decay pathway is an mRNA sur-
veillance system that speciﬁcally recognizes and de-
grades erroneous mRNA that harbors premature ter-
mination codons often resulting from abnormal splicing
or frameshifts (Sun and Maquat 2000). Failure to elim-
inate mRNA with premature termination codons may
result in the translation of aberrant proteins that can
be toxic to cells through dominant-negative or gain-of-
function effects (Wong and Filbin 1996; Frischmeyer
and Dietz 1999; Mendell and Dietz 2001; Holbrook et
al. 2004; Inoue et al. 2004). Essentially all nonsense and
frameshift mutations that are associated with a rela-
tively mild peripheral neuropathy phenotype have their
mRNA degraded because of premature stop codons that
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are detected by nonsense-mediated decay. Therefore,
haploinsufﬁciency is the disease mechanism (Inoue et
al. 2004). Most late-occurring premature termination
codons that result in mRNA that escapes nonsense-me-
diated decay encode apparent dominant-negative or
gain-of-function proteins that convey amore severe neu-
ropathy phenotype. However, a subset of truncating
mutations at the 3′ end of MPZ escapes the nonsense-
mediated decay surveillance pathway and causes a mild
CMT phenotype (ﬁg. 1A) (Inoue et al. 2004; Shy et al.
2004; Inherited Peripheral Neuropathies Mutation Da-
tabase). Thus, the question remains: How can the same
types of mutation—frameshift mutations that escape
nonsense-mediated decay—result in distinct clinical
phenotypes?
We noted an apparent correlation between the type
of frameshift mutations occurring after the transmem-
brane domain and the associated phenotype. Mutations
associated with CMT retain their transmembrane do-
main and have a net addition of a 2 frameshift mu-
tation (a 2-bp insertion or a 1-bp deletion), mainly in
downstream exons (ﬁg. 1A). We hypothesized that
frameshift mutations associated with severe disease may
lead to a mutant protein with a gain-of-function that
causes a more deleterious effect by being misprocessed
in the cell. To examine this hypothesis, we selected four
mutations for functional analyses. These all represent
frameshift alleles that, as we documented elsewhere (In-
oue et al. 2004), escape nonsense-mediated decay and
consist of two mutations from each of two categories:
severe DSN- or CHN-associated mutations (MPZ
506delT and 550del3insG) and relatively mild CMT-
associated mutations (MPZ 554delG and 676insCA)
(ﬁg. 1B). Notably, both 550del3insG and 554delG were
located after the transmembrane domain but differed in
frame and associated phenotype. We introduced such
disease-associated mutations (ﬁg. 1B) in an expression
vector and used both a transiently transfected HeLa cell
line and human embryonic kidney cells (HEK293) to
study the effects of wild-type MPZ cDNA and each
disease-causing mutation on its intracellular processing.
The severe alleles that cause DSN and CHN appear to
be retained in the endoplasmic reticulum (ER) and in-
duce increased apoptotic cell death that can be partially
mitigated by pretreatment with curcumin.
Material and Methods
Recombinant Constructs
Full-length human MPZ cDNA (IMAGE: 3926008)
was obtained (OpenBiosystems) and was subcloned into
pcDNA3.1 (Invitrogen) to generate pcDNAMPZ. Mu-
tations were generated in each construct with use of the
QuikChange site-directed mutagenesis kit (Stratagene).
Clones were veriﬁed by direct double-strand DNA se-
quencing with use of the DyePrimer chemistry and
ABI377 sequencer (Applied Biosystems).
Tissue Culture and Transfection
HeLa cells and HEK293 cells were grown in Dul-
becco’s modiﬁed Eagle medium (BioWhittaker), supple-
mented with 10% fetal bovine serum, and were trans-
fected with use of FuGENE 6 transfection reagents
(Roche Applied Science). Cells were incubated for 24 h
at 37C in a humidiﬁed incubator containing 10% CO2.
Immunostaining
Cells were ﬁxed with 2% paraformaldehyde in PBS
at room temperature for 10 min. Cells were then washed
and permeabilized with 0.1% Triton X-100 in PBS on
ice for 2 min. Cells were rinsed twice with PBS and were
blocked with 5% normal goat serum for 1 h at 37C.
Fixed cells were incubated with primary antibodies di-
luted in PBS with 5% normal goat serum at appropriate
concentrations for 1 h at 37C. Antibodies used in this
study include the polyclonals directed against MPZ pro-
tein (Trapp et al. 1979) and mouse monoclonal protein
disulﬁde isomerase (PDI; 1:1,000 [Afﬁnity Bioreagents]).
This incubation was followed by two washes in PBS and
another incubation with Alexa Fluor goat anti-mouse or
anti-rabbit antibody (1:1,000 [Molecular Probes]) for 1
h at 37C. For visualizing the nuclei, SlowFade Light
Antifade Kit with 4′, 6-diamidino-2-phenylindole (DAPI)
(Molecular Probes) was used in accordance with the
manufacturer’s instructions. Fluorescently labeled cells
were visualized by standard ﬂuorescence microscopy.
Apoptosis Assay
TUNEL staining was performed with use of an in situ
cell death detection kit, Flourescein (Roche Applied Sci-
ence). Cells were grown in four chamber slides and were
ﬁxed with 4% paraformaldehyde in PBS at room tem-
perature for 10 min. Cells were then washed and per-
meablized with 0.1% Triton X-100 in PBS on ice for 2
min. TUNEL staining was performed in accordancewith
conditions recommended by the supplier (1 h at 37C).
The average numbers of TUNEL-positive andDAPI-pos-
itive cells were calculated, and the standard deviation of
the ratio was determined for each slide. Student’s t tests
comparing wild-type andMPZmutants were performed.
Statistical signiﬁcance was deﬁned as .P ! .05
Flow-Cytometric Analysis
Cells were transiently transfected for 48 h and then
harvested. Annexin V–ﬂuorescein isothiocyanate (FITC)
and propidium iodide (PI) staining (BD Biosciences
Pharmingen) was performed by the incubation of cells
(1#106 cells/ml) in the dark for 15 min at room tem-
perature in a binding buffer (10 mM HEPES, 140 mM
Figure 1 Genotype-phenotype correlation of MPZ. A, Published MPZ-truncating mutations that escape nonsense-mediated decay and
are associated with inherited peripheral neuropathies. The six coding exons of MPZ are indicated by shades of blue, and the transmembrane
(TM) domain is encoded by exon 4. Filled triangles, 1 Frameshift mutations. Open triangles,2 Frameshift mutations. Arrows, Altered region
incorporated after frameshift mutations, with X demarcating the new stop codon. Green, CMT1B phenotype. Red, More severe DSN/CHN
phenotype. Note that mutations associated with a severe DSN/CHN phenotype have either an early frameshift that disrupts the transmembrane
domain or a net addition of a 1 frameshift in downstream exons while retaining the transmembrane domain, whereas CMT-associated
mutations have a 2 frameshift in downstream exons. B, Wild-type and mutant MPZ protein sequences investigated in this study. Green, CMT-
associated frameshift mutations. Red, DSN/CHN-associated mutations. Black, Wild-type sequence, with dots representing identity to the wild-
type sequence. The TM domain (in rectangle) and RSTK motif (in boldface) are demarcated in wild-type MPZ.
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Figure 2 Subcellular localization of mutated MPZ proteins in HeLa cells. The HeLa cell line transiently transfected with wild-type MPZ
shows the expression of wild-type MPZ protein on the plasma membrane. Red, DSN/CHN-associated mutations (MPZ mutants 506delT and
550del3InsG) are extensively retained in the ER, as evidenced by colocalization with PDI (f and i, arrows). Note that cells transiently transfected
with these mutants display distinctive apoptotic morphology, including cell shrinkage. Green, CMT-associated MPZ mutations (554delG and
676insCA) are detected on the cell surface as well as in the ER by colocalizing with PDI (l and o, arrows).
NaCl, and 2.5 mM CaCl2, at pH 7.4) containing a sat-
urating concentration of annexin V–FITC and PI. After
incubation, the cells were washed, pelleted, and analyzed
in a FACScan analyzer (Becton Dickinson).
Curcumin Treatment
Curcumin was purchased from Sigma (catalogue num-
ber C7727). Curcumin stock was dissolved in dimethyl
sulfoxide (DMSO) in accordance with conditions rec-
ommended by the supplier. Cells were pretreated with
curcumin (10 mM, unless otherwise indicated) for 3 h
before transfection.
Results
Mutant MPZ Is Retained in the ER
We transiently transfected wild-type MPZ cDNA and
disease-associated mutations (ﬁg. 1B) in different cell
lines to visualize the effects of each disease-causing mu-
tation on its intracellular processing. We performed real-
time PCR on cell lines after transfection and conﬁrmed
comparable levels of gene expression for the mutant and
wild-type constructs (data not shown). In our control
experiments, we veriﬁed that HeLa cell lines transfected
with wild-type MPZ expressed the MPZ protein on the
plasma membrane. We observed similar expression pat-
terns in the HEK293 cell line (data not shown). Of note,
all disease-causing mutants tested had a noticeably ab-
normal intracellular distribution in both cell lines (ﬁg.
2 and data not shown). The distribution of CMT-as-
sociated mutants (MPZ 554delG and MPZ 676insCA)
was different from the wild-type control, in that not only
are the mutant proteins expressed on the cell surface but
they are also detectable in the ER, as shown by colo-
calizing with the ER marker-protein PDI (ﬁg. 2). Al-
though these mutant proteins are expressed on the cell
surface, they are likely to behave as null alleles, because
of the disruption of the protein structure of the basic
cytoplasmic domain (ﬁg. 1B). Interestingly, MPZ mu-
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tants 506delT and 550del3insG were detected only in
the ER, and the staining pattern observed is clearly dif-
ferent from that seen for wild-type and CMT-associated
mutants (ﬁg. 2). The toxic effects of these mutant pro-
teins perhaps do not require translocation to the cell
membrane surface, where normal tetrameric MPZ pro-
teins localize and function.
Severe Disease-Associated MPZ Mutants Cause
Increased Apoptosis
When visualized by light microscopy, cells transfected
with the severe MPZ mutant alleles, 506delT and
550del3insG, display distinctive apoptotic morphology,
including cell shrinkage and detachment from the sur-
face of the plate (data not shown). These observations
led us to consider the possibility that such MPZ early
frameshift mutations have a deleterious effect on cells
and may induce apoptosis. To determine whether cell
death of cells expressing disease-causing MPZ mutants
are apoptotic, we performed TUNEL labeling on cells
transfected with wild-type and MPZ mutants. We quan-
tiﬁed the number of positive cells by counting all TU-
NEL-positive cells and DAPI-positive nuclei in 10 sec-
tions of the chamber slides. We found a large number
of positive cells among those transfected with MPZ
506delT and 550del3insG (DSN- and CHN-associated
mutations) compared with cells expressing either wild-
type or CMT-associated mutations ( andPp .015
, respectively) (ﬁg. 3A).Pp .018
To exclude the possibility that the apoptosis may
represent a nonspeciﬁc consequence of protein overex-
pression, we used the green ﬂuorescent protein (GFP)/
PI assay (Lamm et al. 1997) to analyze the DNA
fragmentation in transiently transfected cells, with GFP
as a marker. Coexpression of MPZ 506delT and
550del3insG resulted in an increase of apoptotic cells to
a level ∼20% higher than that seen with wild-typeMPZ
or CMT-associated mutations (ﬁg. 3B). These ﬁndings
are indicative of a mutation-speciﬁc increase in apoptosis
and are inconsistent with a nonspeciﬁc effect from pro-
tein overexpression.
We also used a combined annexin V–PI staining to
quantify cell apoptosis by an independent method. This
objective assay measures apoptosis via the binding of
FITC-labeled annexin V to phosphatidylserine, as ana-
lyzed by ﬂow cytometry. Phosphatidylserine is normally
conﬁned to the inner leaﬂet of the plasma membrane
and is externalized during apoptosis of many cell types
(Preobrazhensky et al. 2001). The PI staining enables
simultaneous determination of the associated loss of
membrane integrity. Our analyses conﬁrmed that MPZ
506delT and 550del3insG induce apoptosis, with the
annexin V–positive cells reaching 25.6% and 17.1%,
respectively (ﬁg. 3C). In contrast, cells transfected with
wild-type MPZ or CMT-associated mutations contained
a minimal fraction of !7% (ﬁg. 3C). These experiments
clearly support the contention that the latter mutations
conveying a milder CMT phenotype cause a less toxic
effect on cells and, thus, likely act as loss-of-function
alleles.
Curcumin Enhances Mutant MPZ Processing in the ER
These data are consistent with the contention that
MPZ early frameshift mutations associated with severe
disease (ﬁg. 1A) convey a more deleterious effect to the
cell. The severity of the DSN/CHN phenotype is mainly
caused by the more pronounced demyelination or dis-
ruption of the axon–Schwann cell interactions that leads
to axonal loss. This could be due to a misfolding and
mislocalization of MPZ mutants in the ER, possibly by
mechanisms involving certain ER chaperones or a de-
crease in the amount of MPZ available for myelin com-
paction in Schwann cells.
To evaluate a potential reagent’s ability to relieve the
toxic effect associated with severe disease-causing MPZ
frameshift mutations, we investigated the effect of cur-
cumin, a dietary supplement, on MPZ mutants. Cur-
cumin modulates a number of cellular messenger path-
ways, including NF-kB and intracellular calcium (Egan
et al. 2004; Sarkar and Li 2004). Recently, Egan et
al. (2004) have shown that curcumin can apparently
rescue misfolded proteins in both cell cultures and a
homozygous DF508-CFTR mouse model by presumably
interfering with the function of ER calcium-dependent
chaperones (Egan et al. 2004). We hypothesized that cur-
cumin could have a protective effect by causing MPZ-
misfolded and MPZ-aggregated mutants to be released
from the ER, potentially relieving the toxic effect as-
sociated with these mutations in cells. This hypothesis
was experimentally addressed by treating cells express-
ing mutant and wild-type control MPZ with curcumin.
When curcumin was present at low doses (2 mM
and 5 mM), we observed a limited number of cells hav-
ing partial ER release of the severe disease-associated
mutants (MPZ 506delT and 550del3insG) (data not
shown). However, after increasing the concentration of
curcumin to 10 mM, we observed a greater apparent
release from ER retention, mostly to the cytoplasm and
the cell surface (ﬁg. 4A). Notably, we also observed a
signiﬁcant decrease in apoptosis after treating cells with
10 mM of curcumin (ﬁg. 4B and 4C). The percentage of
apoptotic cells after curcumin treatment is essentially the
same as that observed for the control wild-type MPZ
protein and is signiﬁcantly different from that observed
for these mutants without curcumin treatment (ﬁg. 3C).
These data indicate that curcumin treatment abrogates
the ER retention and aggregation-induced apoptosis as-
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Figure 3 Increased cell death in HeLa cell lines after transfection with mutant MPZ. A, Apoptosis induced in HeLa cell lines after transient
transfection with MPZ 506delT (c) and 550del3insG (d). Cell lines transfected with wild-type MPZ (b), MPZ 554delG (e), and MPZ 676insCA
(f) show a signiﬁcantly lower number of positive cells. Data from TUNEL assays revealed the presence of more positive cells only after transfection
with DSN/CHN-associated mutations (c and d). A negative control (a) is also shown. B, DSN/CHN-associated mutations (MPZ 506delT and
550del3insG) increased the number of apoptotic cells, compared with wild-type MPZ. Bar graph shows results for severe (red) and relatively
mild (green) mutant alleles SD for each of four independent experiments ( ). C, Representative study of the ﬂow-cytometric analysis ofnp 4
apoptosis after transfecting cells with wild-type MPZ and disease-associated mutations. Signiﬁcant differences were observed in the percentage
of cells undergoing apoptosis when transfected with 506delT and 550del3insG (DSN/CHN-associated mutations), whereas CMT-associated
mutations show a less toxic effect on cells. Note that overexpression of wild-type MPZ induces measurable apoptosis, compared with the
negative control (representative data from one of three independent experiments with comparable results; FS p ﬂow-sorted cells and PI p
propidium iodide).
sociated with neuropathy-causing MPZ-truncating mu-
tants observed in cells.
Discussion
More than 90 different point mutations in MPZ that
result in a spectrum of inherited demyelinating neurop-
athies, including CMT, DSN, and CHN (Inherited Pe-
ripheral Neuropathies Mutation Database), have been
identiﬁed. The identiﬁcation and evaluation of these mu-
tations in patients with different clinical severities not
only has provided insights into the role ofMPZ inmyelin
structure (Warner et al. 1996) but has also enabled ge-
notype/phenotype correlations (Inoue et al. 2004; Shy
et al. 2004). Various nonsense and frameshift mutations
in MPZ result in both mild and severe forms of neu-
ropathy, and we previously demonstrated thatmutations
in ORFs could dictate disease severity by mechanisms
other than effects on the protein product (Inoue et al.
2004).
Most MPZ-truncating mutations associated with
a more severe form of peripheral neuropathy result
in premature termination codons within the terminal
or penultimate exons and are thus not detected by the
nonsense-mediated decay surveillance pathway. Such
mRNA is translated into mutant proteins with potential
dominant-negative activity. However, a subset of pre-
mature termination codon mutations at the 3′ end of
MPZ escapes the nonsense-mediated decay pathway
and the mRNA is translated into mutant protein, but
a mild peripheral neuropathy phenotype results. Here,
we provide experimental evidence that the escape from
nonsense-mediated decay does not necessarily result in
a more severe phenotype and that the phenotypic out-
come depends on the function of mutant proteins. Fur-
thermore, we demonstrate that curcumin, a dietary sup-
plement, apparently stimulates the translocation of
intracellularly retained mutant MPZ from the ER to the
plasma membrane, clearly reducing cytotoxicity of the
mutant protein, as evidenced by a decreased percentage
of apoptotic cells (ﬁg. 4).
CMT-associated mutants are expressed on the cell
surface but convey only a minor toxic effect, as evi-
denced by apoptosis assays, and, thus, may function as
loss-of-function alleles. The mild phenotype produced
by these mutants suggests that they do not interfere with
tetramer formation and do allow wild-type MPZ mol-
ecules to partly restore myelin function. CMT-associ-
ated mutants thus likely act as null alleles or possess a
reduced level of activity because of the disruption of the
protein structure of the basic cytoplasmic domain. The
cytoplasmic domain of MPZ is extremely basic and has
been shown to stabilize adhesion between the intracel-
lular components of the plasma membrane in myelin by
interacting with the apposing anionic lipid bilayer to
help in the formation of the major dense line (Ding and
Brunden 1994; Martini et al. 1995a). The cytoplasmic
domain contains a PKC target motif (RSTK), and this
property of the intracellular domain can be extensively
affected by changes in some amino acids critical to hom-
ophilic interactions (Xu et al. 2001).
In contrast, mutations associated with severe DSN/
CHN cause a more deleterious effect to the cells by
being associated with ER retention (ﬁg. 2) and apparent
aggregation-induced apoptosis (ﬁg. 3). Such MPZ mu-
tants may also indirectly affect wild-type MPZ cell-tar-
geting to myelin. In fact,Mpz/ heterozygous knockout
mice show normal myelination at an early age because
of the partial expression of wild-type Mpz molecules,
whereas a lack of MPZ expression could account for
the severe phenotype, which has been observed in null
Mpz/mice (Giese et al. 1992; Martini et al. 1995b).
The gene dosage dependence of wild-type MPZ for
proper myelin maintenance has also been observed in
heterozygous MPZ-truncated mutations in parents who
presented with a CMT1 phenotype, whereas the ho-
mozygous children had a more severe DSN phenotype
(Warner et al. 1996).
We provide evidence that, by treating cells with cur-
cumin, we could abrogate the ER retention of selected
MPZ mutants enough to ameliorate the toxic effect, as
determined by apoptosis assays, associated with these
mutations (ﬁg. 4). Previous studies have shown that
some mutant MPZ aggregates colocalize with BiP, an
HSP70 chaperone in the lumen of the ER, but not with
calnexin (Matsuyama et al. 2002; Shames et al. 2003).
Figure 4 Release of ER-retained MPZ mutants with curcumin treatment. A, Curcumin treatment of HeLa cells rescues MPZ 506delT
(d) and 550del3insG (f) mutants (in green) retained in the ER (PDI markers in red) to the cytoplasm. Interestingly, mutant MPZ 506delT (d,
arrow) was detectable only in the cytoplasm, mainly because of the disruption of the transmembrane domain in this mutant protein. Note that
cells treated with 10 mM curcumin showed reduced ER retention and mostly cytoplasmic localization for MPZ mutants (d and f, arrows). B,
Apoptosis analysis of cells transiently transfected with wild-type MPZ mutations 506delT and 550del3insG after curcumin treatment. C, Bar
graph of wild-type (black) and severe (red) alleles treated with curcumin, showing averageSD from three independent experiments, as shown
in panel B. Cells undergo less apoptosis when treated with curcumin (n p 3). DMSO alone, at the same concentration used in our curcumin
preparation, had no toxic effect on cells (data not shown).
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The involvement of mutant proteins with BiP is often
associated with activation of the “unfolded protein re-
sponse,” which leads to the upregulation of certain ER
chaperones and interference with folding of newly syn-
thesized proteins that, under stress conditions, could be
detrimental to cell growth and survival (Little and Lee
1995; Gething 1999). Although the mechanism through
which curcumin corrects the processing and function of
misfolded or aggregated mutant proteins in cells is not
yet determined, it is hypothesized that it may interfere
with the function of the ER calcium-dependent chap-
erones by altering the calcium levels in the ER (Egan et
al. 2004). However, one study brings into question this
purported mechanism for the curcumin effect (Song et
al. 2004). Nevertheless, other recent reports document
the correction of impaired folding mutations (Teijido et
al. 2004) and the inhibition of aggregation formation
(Yang et al. 2004) after curcumin treatment. We now
document in cell culture the apparent release of proteins
with severe MPZ alleles from ER retention, and we
demonstrate less apoptosis for curcumin-treated mis-
folding mutants. These ﬁndings suggest that curcumin
treatment may be sufﬁcient to relieve the toxic effects
associated with severe disease-causing MPZ mutations
in whole animals.
Our observations could potentially be relevant for
patients with severe peripheral neuropathies that result
from protein misfolding in the ER, including those
caused by MPZ, Cx32 (Deschenes et al. 1997), PMP22
(Naef et al. 1997; D’Urso et al. 1998; Dickson et al.
2002; Ryan et al. 2002), or a host of other proteins
encoded by disease-associated CMT genes (Saiﬁ et al.
2003; Szigeti and Lupski, in press). Although curcumin
shows utility in cell culture, further studies are required
in transgenic mouse models to evaluate its potential use
for therapy of peripheral neuropathy disorders.
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